Key result
Beta-2 adrenergic receptor agonists and phosphodiesterase inhibitors decreased DUX4 expression by >75% in FSHD patient-derived myotubes through a protein kinase A-dependent mechanism.
Activation of protein kinase A via beta-2 adrenergic receptor agonists or phosphodiesterase inhibitors significantly reduces DUX4 expression in FSHD patient-derived myotubes, offering a potential therapeutic pathway.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for PKA activation in FSHD; does not support clinical use of beta-2 agonists or PDE inhibitors.
Facioscapulohumeral muscular dystrophy (FSHD) is among the most prevalent of the adult-onset muscular dystrophies. FSHD causes a loss of muscle mass and function, resulting in severe debilitation and reduction in quality of life. Currently, only the symptoms of FSHD can be treated, and such treatments have minimal benefit. The available options are not curative, and none of the treatments address the underlying cause of FSHD. The genetic, epigenetic, and molecular mechanisms triggering FSHD are now quite well-understood, and it has been shown that expression of the transcriptional regulator double homeobox 4 (DUX4) is necessary for disease onset and is largely thought to be the causative factor in FSHD. Therefore, we sought to identify compounds suppressing DUX4 expression in a phenotypic screen using FSHD patient-derived muscle cells, a zinc finger and SCAN domain-containing 4 (ZSCAN4)-based reporter gene assay for measuring DUX4 activity, and 3,000 small molecules. This effort identified molecules that reduce DUX4 gene expression and hence DUX4 activity. Among those, 2 -adrenergic receptor agonists and phosphodiesterase inhibitors, both leading to increased cellular cAMP, effectively decreased DUX4 expression by >75% in cells from individuals with FSHD. Of note, we found that cAMP production reduces DUX4 expression through a protein kinase A-dependent mode of action in FSHD patient myotubes. These findings increase our understanding of how DUX4 expression is regulated in FSHD and point to potential areas of therapeutic intervention.
No takes yet. Share an insight, caveat, or question.
Cruz et al. (2018) studied Facioscapulohumeral muscular dystrophy (FSHD). Beta-2 adrenergic receptor agonists and phosphodiesterase inhibitors was evaluated on DUX4 gene expression. Beta-2 adrenergic receptor agonists and phosphodiesterase inhibitors decreased DUX4 expression by >75% in FSHD patient-derived myotubes through a protein kinase A-dependent mechanism.
Synapse has enriched 10 related papers. Consider them for comparative context: